Tocagen's brain cancer treatment fails late-stage study


(Reuters) – Tocagen Inc said on Thursday its experimental treatment did not prove effective in helping patients with a type of brain cancer to live longer, in a late-stage study.

The California-based company said in the trial its lead product candidate Toca 511 & Toca FC also did not show meaningful superiority in secondary goals compared to standard of care treatment.

Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli

Our Standards:The Thomson Reuters Trust Principles.


Please enter your comment!
Please enter your name here